Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma

Head-to-head comparison of the blood-based EasyM clonotypic mass-spectrometry assay with EuroFlow bone-marrow MRD in myeloma (Haematologica 2025). The PubMed record did not include a structured abstract with numeric concordance rates at retrieval, so rates are not restated here; the paper and DOI were verified.

HaematologicaPubMed 39506908